Job Seeker: Login Sign Up
`
`Employer: Login Post Jobs
`
`HOME
`
`NEWS
`
`JOBS
`
`CAREER RESOURCES
`
`HOTBEDS
`
`CAREER EVENTS
`
`EVENTS
`
`COMPANY PROFILES
`
`INVESTORS
`
`Search Life Sciences Jobs
`Job Title, Keyword or Company Name
`City, State, or Postal Code
`
`FIND JOBS
`
`>>
`
`(cid:97)News | News By Subject | News by Disease |(cid:97) News By Date | Search News
`
`Get Our FREE
`Industry eNewsletter
`
`(cid:97)
`
`email:
`
`(cid:97)
`
`Novartis AG Stops Lung Cancer Drug Trial of ASA404,
`Developed in Partnership with Antisoma PLC(cid:97)(ASM.L),
`Books $120 Million Charge
`
`
`
`Tweet
`
`
`
`Share
`
`
`
`
`
`11/11/2010 7:45:41 AM
`
`LONDON and CAMBRIDGE, MA--(Marketwire - November 11, 2010) - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that
`
`a scheduled interim analysis showed that the ATTRACT- 2 trial should stop as ASA404 was unlikely to provide any bene(cid:210)t as a
`
`second-line treatment for non-small cell lung cancer.
`
`Glyn Edwards, CEO of Antisoma, said: "The (cid:210)ndings from ATTRACT-2 mirror those from ATTRACT-1 and therefore come as no
`
`surprise. Our focus for some time has been on other programmes, most notably AS1413, which reports phase III data in the
`
`(cid:210)rst half of next year."
`
`Except for the historical information presented, certain matters discussed in this announcement are forward looking
`
`statements that are subject to a number of risks and uncertainties that could cause actual results to di(cid:215)er materially from
`
`results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be
`
`associated with product discovery and development, including statements regarding the company's clinical development
`
`programmes, the expected timing of clinical trials and regulatory (cid:210)lings. Such statements are based on management's current
`
`expectations, but actual results may di(cid:215)er materially.
`
`About the ATTRACT studies in non-small cell lung cancer (NSCLC) ATTRACT-2 was a pivotal study carried out by Novartis to
`
`evaluate ASA404 in previously treated, advanced NSCLC. Patients were randomised to receive either ASA404 plus docetaxel
`
`or a placebo plus docetaxel as a control. A separate study, ATTRACT-1, had investigated ASA404 as a (cid:210)rst-line treatment for
`
`NSCLC.
`
`About ASA404
`
`ASA404 (vadimezan, formerly known as DMXAA and AS1404) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-
`
`VDA) which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William
`
`Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-
`
`1
`
`OSI EXHIBIT 2012
`APOTEX V. OSI
`IPR2016-01284
`
`

`
`licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and
`
`commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in 2001. Worldwide rights to the
`drug were licensed to Novartis AG in April 2007.
`
`About Antisoma
`
`Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of
`
`cancer. The Company has operations in the UK and the US. Please visit www.antisoma.com for further information about
`
`Antisoma.
`
`[HUG#1461272]
`
`This announcement is distributed by Thomson Reuters on behalf of
`
`Thomson Reuters clients. The owner of this announcement warrants that:
`
`(i) the releases contained herein are protected by copyright and other applicable laws; and
`
`(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
`
`Source: Antisoma plc via Thomson Reuters ONE
`
`Enquiries:
`
`Glyn Edwards
`
`CEO
`
`Daniel Elger
`
`VP Marketing & Communications
`
`+44 (0)7909 915 068
`
`Antisoma plc
`
`Mark Court/Jessica Fontaine
`
`+44 (0)20 7466 5000
`
`Buchanan Communications
`
`2